MX2019009227A - Métodos para tratar cáncer con inhibidores de hsp90. - Google Patents
Métodos para tratar cáncer con inhibidores de hsp90.Info
- Publication number
- MX2019009227A MX2019009227A MX2019009227A MX2019009227A MX2019009227A MX 2019009227 A MX2019009227 A MX 2019009227A MX 2019009227 A MX2019009227 A MX 2019009227A MX 2019009227 A MX2019009227 A MX 2019009227A MX 2019009227 A MX2019009227 A MX 2019009227A
- Authority
- MX
- Mexico
- Prior art keywords
- hsp90 inhibitors
- treating cancer
- methods
- inhibitors
- disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762454113P | 2017-02-03 | 2017-02-03 | |
| US201762563991P | 2017-09-27 | 2017-09-27 | |
| US201762587886P | 2017-11-17 | 2017-11-17 | |
| PCT/US2018/016361 WO2018144680A1 (en) | 2017-02-03 | 2018-02-01 | Methods for treating cancer using hsp90 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009227A true MX2019009227A (es) | 2020-02-12 |
Family
ID=63038389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009227A MX2019009227A (es) | 2017-02-03 | 2018-02-01 | Métodos para tratar cáncer con inhibidores de hsp90. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10799508B2 (enExample) |
| EP (1) | EP3576794A1 (enExample) |
| JP (1) | JP2020505433A (enExample) |
| KR (1) | KR20190110128A (enExample) |
| CN (1) | CN110536702A (enExample) |
| AU (1) | AU2018215336A1 (enExample) |
| BR (1) | BR112019016024A2 (enExample) |
| CA (1) | CA3052594A1 (enExample) |
| IL (1) | IL268430A (enExample) |
| MX (1) | MX2019009227A (enExample) |
| RU (1) | RU2019127350A (enExample) |
| TW (1) | TW201840337A (enExample) |
| WO (1) | WO2018144680A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505433A (ja) | 2017-02-03 | 2020-02-20 | エイアイ・セラピューティクス・インコーポレーテッド | Ｈｓｐ９０阻害剤を使用してがんを治療するための方法 |
| BR112020006009A2 (pt) * | 2017-09-27 | 2020-10-06 | Al Therapeutics, Inc. | métodos terapêuticos relacionados a inibidores de hsp90 |
| BR112021007823A2 (pt) * | 2018-11-08 | 2021-07-27 | Glaxosmithkline Intellectual Property Development Limited | combinação de inibidores da prmt5 e inibidores do bcl-2 |
| AU2020214802A1 (en) | 2019-01-29 | 2021-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022540317A (ja) * | 2019-06-25 | 2022-09-15 | ターベダ セラピューティクス インコーポレイテッド | Ｈｓｐ９０結合コンジュゲートおよびその併用療法 |
| PH12022551091A1 (en) | 2019-11-05 | 2024-06-24 | Abbvie Deutschland | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| WO2021157650A1 (ja) * | 2020-02-05 | 2021-08-12 | カルナバイオサイエンス株式会社 | 抗がん剤組成物 |
| KR102683903B1 (ko) * | 2020-09-16 | 2024-07-12 | 한국원자력의학원 | 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물 |
| CN116615195A (zh) * | 2020-09-17 | 2023-08-18 | 阿尔伯爱因斯坦医学院 | 使用bax激活剂的组合治疗 |
| IL301322A (en) * | 2020-09-17 | 2023-05-01 | Albert Einstein College Medicine | Combination therapy using bax activator agent |
| WO2023060137A2 (en) * | 2021-10-05 | 2023-04-13 | Board Of Regents, The University Of Texas System | Methods and compositions comprising b7-h3 binding polypeptides |
| CN114588269B (zh) * | 2022-04-06 | 2023-06-27 | 宁波大学附属人民医院 | Bcl-2抑制剂和HDAC抑制剂的组合物及其用途 |
| WO2024006292A2 (en) * | 2022-06-27 | 2024-01-04 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| CN115957328A (zh) * | 2022-07-13 | 2023-04-14 | 杭州百可生物科技有限公司 | 一种用于治疗白血病的药物组合物以及白血病的治疗方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060253A2 (en) | 2009-11-13 | 2011-05-19 | Myrexis, Inc. | Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms |
| CN103002895A (zh) * | 2010-02-12 | 2013-03-27 | 尼基制药公司 | 治疗血液癌症的方法 |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| NZ618062A (en) * | 2011-04-28 | 2016-04-29 | Sloan Kettering Inst Cancer | Hsp90 combination therapy |
| JP2020505433A (ja) | 2017-02-03 | 2020-02-20 | エイアイ・セラピューティクス・インコーポレーテッド | Ｈｓｐ９０阻害剤を使用してがんを治療するための方法 |
| BR112020006009A2 (pt) | 2017-09-27 | 2020-10-06 | Al Therapeutics, Inc. | métodos terapêuticos relacionados a inibidores de hsp90 |
-
2018
- 2018-02-01 JP JP2019542191A patent/JP2020505433A/ja not_active Withdrawn
- 2018-02-01 EP EP18704808.7A patent/EP3576794A1/en not_active Withdrawn
- 2018-02-01 WO PCT/US2018/016361 patent/WO2018144680A1/en not_active Ceased
- 2018-02-01 MX MX2019009227A patent/MX2019009227A/es unknown
- 2018-02-01 KR KR1020197025467A patent/KR20190110128A/ko not_active Ceased
- 2018-02-01 CA CA3052594A patent/CA3052594A1/en not_active Abandoned
- 2018-02-01 CN CN201880023110.6A patent/CN110536702A/zh active Pending
- 2018-02-01 AU AU2018215336A patent/AU2018215336A1/en not_active Abandoned
- 2018-02-01 BR BR112019016024-8A patent/BR112019016024A2/pt not_active Application Discontinuation
- 2018-02-01 US US15/885,975 patent/US10799508B2/en not_active Expired - Fee Related
- 2018-02-01 RU RU2019127350A patent/RU2019127350A/ru not_active Application Discontinuation
- 2018-02-01 TW TW107103636A patent/TW201840337A/zh unknown
-
2019
- 2019-08-01 IL IL268430A patent/IL268430A/en unknown
-
2020
- 2020-09-23 US US16/948,537 patent/US20210030759A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019127350A (ru) | 2021-03-03 |
| TW201840337A (zh) | 2018-11-16 |
| JP2020505433A (ja) | 2020-02-20 |
| WO2018144680A1 (en) | 2018-08-09 |
| KR20190110128A (ko) | 2019-09-27 |
| RU2019127350A3 (enExample) | 2021-05-31 |
| CN110536702A (zh) | 2019-12-03 |
| US20210030759A1 (en) | 2021-02-04 |
| CA3052594A1 (en) | 2018-08-09 |
| US10799508B2 (en) | 2020-10-13 |
| EP3576794A1 (en) | 2019-12-11 |
| IL268430A (en) | 2019-09-26 |
| US20180221376A1 (en) | 2018-08-09 |
| BR112019016024A2 (pt) | 2020-03-31 |
| AU2018215336A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2022001075A (es) | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX382162B (es) | Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer. | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| MX2019013862A (es) | Terapia de combinacion. | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |